Research into a potential cancer vaccine has given encouraging initial results, Powderject Pharmaceuticals said. Its scientific collaborators at the Memorial Sloan-Kettering Cancer Center in the US showed that vaccination with a "differentiation antigen", using Powderject's technology, "may boost the immune system so that it can recognise and destroy cancerous cells not previosuly recognized as cancerous".